LIONHEART
LONGEVITY & WELLNESS

12-MONTH WELLNESS RESEARCH

U.S. + INTERNATIONAL STUDY DESIGN

KLOTHO-UP

Lionheart Health Wellness Study

Exploring a combined approach to circulating Klotho and healthspan

MUSCLE
Function & strength

BRAIN
Cognition & memory

IMMUNITY
Immune health

12 months • Open-label • Non-randomized • Interventional feasibility study

U.S. CORE ARM

U.S. IRB approved

- Bioelectric neuromuscular stimulation and enhanced exercise, generally 2-3 sessions weekly.
- Klotho-promoting nutrition plus daily Rejuvant™, personalized SNIP Nutrition and Klotho-support supplements.
- Optional targeted bioelectric therapies for joint, sexual, skin, hair/scalp, gut, vision, hearing, bladder, kidney, blood pressure and inflammation health.
- Research peptides, including Klotho peptides, only as permitted by the approved protocol and applicable U.S. law, with separate participant consent.

INTERNATIONAL ADVANCED ARM

Separate IRB approval required in each clinic country

- Physician-directed AAV gene therapy targeting Klotho, hTERT and Follistatin.
- Personalized peptide longevity stack, including Klotho peptides, alongside bioelectric stimulation and lifestyle support.
- Optional Klotho and other exosomes; U.S.-sourced, pre-differentiated cell sources preferred.
- Optional umbilical cord stem cells, encapsulated MSCs and Klotho-expressing stem cells.
- Additional safety monitoring and local regulatory and ethics requirements apply.

ASSESSMENTS & OUTCOMES

BASELINE → 3 MONTHS → 6 MONTHS → 12 MONTHS

Primary: muscle strength, walking performance, muscle mass, cognition, memory, mood, immune and inflammatory markers, and circulating Klotho. Includes extensive biomarkers, microbiome testing and imaging.

Secondary: vision, hearing, joint pain, sexual health, skin elasticity, hair density, sleep, stress, bladder health and exercise capacity.

Ask your clinic study team about participation and the approved local protocol.

The study evaluates feasibility, safety and changes in healthspan-related outcomes. IRB approval supports research under the approved protocol; it does not constitute FDA approval of new treatment indications. Benefits are not established or guaranteed.